Browse > Home / Archive by category 'Resources'

qNPA™ Technology Animation

Click here to view a Technical Animation of the qNPA™ ArrayPlate.

 

Technology Information

Academic Research

Applications
FFPE Tissue in the qNPA ArrayPlate System
miRNA in the qNPA Arrayplate

Brochures
High Throughput Gene Expression Analysis
Measuring miRNA with qNPA Technology 

Instruments
Capella Imager
Omix II Imager

Products
qFix qNPA ArrayPlate

Drug Discovery

Applications
FFPE Tissue in the qNPA ArrayPlate System
miRNA in the qNPA Arrayplate

Brochures
Multiplexed Biomarker-Driven Drug Discovery
Measuring miRNA with qNPA Technology 

Instruments
Omix HD Imager

Products
qFix qNPA ArrayPlate

 

Recent Publications

1. Martel, R., Botros, I., Rounseville, M., et al, (2002). Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. Assay and Drug Development Technologies, 1 (1-1):61-71.

2. Martel, R., Rounseville, M., Botros, I., et al, (2002). Multiplexed Chemiluminescence Assays in ArrayPlates for High-Throughput Measurement of Gene Expression, Progress in Bimedical Optics and Imaging, 3:35-43.

3. Martel. R., Rounseville, M., Botros, I., et al, (2002). “Multiplexed Molecular Profiling (MMP) Transcription Assay in ArayPlates for High-Throughput Measurement of Gene Expression.” Gene Cloning and Expression Technologies, Q. Lu and M. Weiner, Eds., Eaton Publishing, Natick.

4. Seligmann, B., (2003). “Mining the Transcriptome Using High-Throughput Multiplexed mRNA Profiling.” PharmacoGenomics, 3:36-43.

5. Martel, R., Staples, R., Hinton, J., et al, (2003). “Array Formats” in “Microarray Technologies and Applications”, Microarray Technologies and Applications, Springer-Verlag, Heidelberg.

6. Sawada, H., Taniguchi, K., Takami, K., et al, (2006). “Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay”. Toxicology in Vitro, 20:1506-1513.

7. Bakir, F., Kher, S., Pannala, M., et al, (2007). “Discovery and structure–activity relationship studies of indole derivatives as liver X receptor (LXR) agonists” Biorg and Med Chem Letters, 17: 3473-3479.

8. Kris, R., Felder, S., Deyholos, M., et al, (2007). “High-Throughput, High-Sensitivity Analysis of Gene Expression in Arabidopsis” Plant Physiol. 144: 1256-1266.

9. Roberts, R., Sabalos, C., Martel, R., et al, ( 2007). “Quantitative Nuclease Protection Assay in Paraffin-Embedded Tissue Replicates Prognostic Microarray Gene Expression in Diffuse Large-B-Cell Lymphoma” Laboratory Investigation, 87: 979-997.

10. Rimsza, L., LeBlanc, M., Unger, J., et al., (2008). “Gene expression predicts overall survival in paraffin embedded tissues of diffuse large B cell lymphoma treated with R-CHOP” Blood, Online June 10, 2008 doi: 10.1182/blood-2008-02-137372.

11. Altar CA, Hunt RA, Jurata LW, Webster MJ, Derby E, Gallagher P, Lemire A, Brockman J, Laeng P (2008). “Insulin, IGF-1, and muscarinic agonists modulate schizophrenia-associated genes in human neuroblastoma cells.” Biological Psychiatry, 64:1077-1087.

12. Fichorova, R. N., Trifonova, R. T., Doncel, G. F., (2009) “Polyanionic Microbicides Modify
Toll-Like Receptor-Mediated Cervicovaginal Immune Responses.” Antimicrobial Agents and
Chemotherapy, April 2009: 1490-1500.

13. Altar CA, Vawter MP, Ginsberg SD (2009). “Target identification for CNS diseases by transcriptional profiling.” Neuropsychopharmacology, 34:18-54.

14. Pechold S, Stouffer M, et. al., (2009) “Transcriptional analysis of intracytoplasmically stained, FACS-purified cells by high throughput, quantitative nuclease protection.” Nature Biotechnology, 27, 1038-1042.

 

Trademarks

Capella, SuperCapella, Omix, OMIX HD, qCustom, qFix, qSelect, and qNPA are trademarks of High Throughput Genomics, Inc. For questions regarding the usage of the marks, please contact feedback@htgenomics.com .

 

Intellectual Property

HTG has intellectual properties associated with four advanced and innovative technologies including:

  • Universal Arrays
  • Quantitative Nuclease Protection Assay (qNPA™)
  • Array printing
  • Hybridization acceleration

Microarrays have transformed pharmaceutical research and development and life science research by allowing scientists to measure many different molecules in a single sample simultaneously.

Yet, while high-density microarrays have been valuable in identifying potential gene targets, their imprecision, cost, and the lack of consistency between the microarrays available from different vendors have limited their use for other aspects of drug discovery and diagnostics.

HTG’s ArrayPlate™ product is based on Universal Array IP, a technology that provides scientists, researchers and technicians with the flexibility to customize an ArrayPlate on the bench top using a simple reagent-addition protocol to measure a unique set of targets.

HTG technology combines the Universal Array with its quantitative Nuclease Protection Assay (qNPA) to provide clients with a breakthrough quantitative gene expression platform.  The ArrayPlate product, based on these two technologies, delivers the Universal Array’s flexibility and qNPA’s excellent sensitivity, quantitative accuracy, precision and multiplexed, high-sample throughput to significantly enhance gene expression measurement.